EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate Patients
The revised trial design focuses on evaluating Teverelix, a GnRH antagonist, for preventing recurrent acute urinary retention in men with benign prostatic hyperplasia.
Open original source